Clinical trials indicate that the CXCR4 inhibitor LY2510924 targets the CXCL12-CXCR4 axis, exhibits a favorable safety profile, and is well tolerated in patients with colorectal cancer, pancreatic cancer, and other solid tumors (143). Here, CXCR4 is linked to familial pancreatic carcinoma.